Trials / Completed
CompletedNCT03747575
A Study to Assess the Efficacy and Safety of MSTT1041A in Participants With Moderate to Severe Atopic Dermatitis
A Phase II, Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Assess the Efficacy and Safety of MSTT1041A in Patients With Moderate to Severe Atopic Dermatitis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 65 (actual)
- Sponsor
- Genentech, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study will assess the efficacy and safety of MSTT1041A (astegolimab) in participants with moderate to severe atopic dermatitis (AD). The study consists of a screening period, a 16-week treatment period, and an 8-week follow-up period.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MSTT1041A | Participants will receive subcutaneous (SC) MSTT1041A |
| DRUG | Placebo | Participants will receive SC placebo |
Timeline
- Start date
- 2019-02-06
- Primary completion
- 2020-03-11
- Completion
- 2020-05-05
- First posted
- 2018-11-20
- Last updated
- 2023-05-06
- Results posted
- 2023-05-06
Locations
21 sites across 3 countries: United States, Germany, Poland
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03747575. Inclusion in this directory is not an endorsement.